135 related articles for article (PubMed ID: 21752038)
1. Liver stiffness diminishes with antiviral response in chronic hepatitis C.
Hézode C; Castéra L; Roudot-Thoraval F; Bouvier-Alias M; Rosa I; Roulot D; Leroy V; Mallat A; Pawlotsky JM
Aliment Pharmacol Ther; 2011 Sep; 34(6):656-63. PubMed ID: 21752038
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
Stasi C; Arena U; Zignego AL; Corti G; Monti M; Triboli E; Pellegrini E; Renzo S; Leoncini L; Marra F; Laffi G; Milani S; Pinzani M
Dig Liver Dis; 2013 Oct; 45(10):840-3. PubMed ID: 23660078
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
4. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
[TBL] [Abstract][Full Text] [Related]
5. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
[TBL] [Abstract][Full Text] [Related]
6. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
7. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
8. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
Lee HW; Chon YE; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Jung KS; Park YN; Han KH
Gut Liver; 2016 May; 10(3):429-36. PubMed ID: 26347515
[TBL] [Abstract][Full Text] [Related]
9. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
10. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
11. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
Sáez-Royuela F; Linares P; Cervera LA; Almohalla C; Jorquera F; Lorenzo S; García I; Karpman G; Badia E; Vallecillo MA; Moncada A; Calvo S; Olcoz JL;
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):305-12. PubMed ID: 26636405
[TBL] [Abstract][Full Text] [Related]
15. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.
Giusto M; Rodriguez M; Navarro L; Rubin A; Aguilera V; San-Juan F; Ortiz C; López-Andujar R; Prieto M; Berenguer M
Liver Transpl; 2011 Nov; 17(11):1318-27. PubMed ID: 21761553
[TBL] [Abstract][Full Text] [Related]
16. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Ogawa E; Furusyo N; Toyoda K; Takeoka H; Maeda S; Hayashi J
Antiviral Res; 2009 Aug; 83(2):127-34. PubMed ID: 19443053
[TBL] [Abstract][Full Text] [Related]
17. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
18. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
[TBL] [Abstract][Full Text] [Related]
19. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Giannini EG; Basso M; Savarino V; Picciotto A
Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
[TBL] [Abstract][Full Text] [Related]
20. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
